Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee

Lown, Robert; Philippe, Jennifer; Navarro, Willis H.; Walraven, Suzanna M. van; Philips-Johnson, L; Fechter, Mirjam; Pawson, Rachel; Bengtsson, Mats; Beksaç, Meral; Field, Stephen; Yang, Hung‐Chih; Shaw, Bronwen E.

doi:10.1038/bmt.2014.67

Cited by 44 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association with G‐CSF could not be proven in the latter Case . G‐CSF‐related temporal atypical inflammatory response presenting with fever, low back pain, lymphadenomegaly, and leukocytosis was reported in a healthy donor …”

Section: Discussionmentioning

confidence: 88%

“…27 G-CSF-related temporal atypical inflammatory response presenting with fever, low back pain, lymphadenomegaly, and leukocytosis was reported in a healthy donor. 28 Hematological parameters are within normal ranges in individuals with Hemoglobin S trait. However, these individuals are susceptible to some environmental conditions including strenuous sports such as fitness, insufficient fluid intake, alcohol use, and low oxygen pressure.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Gereklioğlu

Asma

Korur

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

Background and Objective: Assessment of Hemoglobin S trait donors has gained importance together with the increased allogeneic peripheral stem cell transplant activity for sickle cell disease in the regions where the disease is prevalent. Outcomes of Granulocyte-Colony Stimulating Factor (G-CSF) administration are obscure for hemoglobin S trait donors. This study aims at investigating the incidence of hemoglobin S carrier status and outcomes of G-CSF administration among donors who live in Eastern Mediterranean region.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 97%

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Gereklioğlu

Asma

Korur

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…The same applies for patients with blast crisis. Disease, transplant, and economic risks need to be assessed [21,35,37,38,[66][67][68]. Patients with high transplant risks should not be entered into long-lasting unsuccessful donor searches to end with HSCT in desperation without any reasonable likelihood for success.…”

Section: Discussionmentioning

confidence: 99%

“…Hence, the general statement that the probability of survival after an allogeneic HSCT for CML at 5 years is 60 % is of limited value; it might range from more than 90 % to less than 5 %. As we will see below, integration of all elements, including macroeconomic factors of patient's location, should impact on choice of transplant technique and the final decision to proceed with HSCT or to abstain from it [34][35][36][37][38][39].…”

Section: Outcome Of Hsct For CMLmentioning

confidence: 99%

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

2015

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently recommended as 2nd or 3rd line therapy for patients with chronic myeloid leukemia (CML) in first chronic phase or as salvage for patients with very advanced disease. As a consequence, numbers of HSCT in chronic phase have dropped significantly since the introduction of tyrosine kinase inhibitors (TKI), numbers of transplants in advanced disease to a lesser extent. These current recommendations consider primarily disease risk, defined as failure of TKI therapy; they might need to be adapted. We propose a more balanced appraisal of HSCT for individual patients which should include disease risk, transplant risk, and macroeconomic aspects. HSCT should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk. For patients with very advanced disease and high transplant risk in contrast, HSCT might only be recommended in a restricted research setting.

show abstract

“…8,9 Many of these registries have also recently revised the upper age limit for joining a registry downward to 40–although this is primarily due to better patient outcomes when younger donors are used rather than donor safety concers. 10–12 No such guidelines exist for related donors, and an aging population, the increasing use of haploidentical transplantation, and improvements in transplant-related regimens make it likely that the use of older sibling donors will continue to increase. Despite this, there are no existing large systematic investigations of health-related quality of life (HRQoL) in the context of older related HSC donation.…”

Section: Introductionmentioning

confidence: 99%

Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study

Switzer

Bruce

Kiefer

et al. 2017

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The increasing number of older adults with blood-related disorders and the introduction of reduced intensity conditioning regimens has led to increases in hematopoietic stem cell (HSC) transplantation among older adults and a corresponding increase in the age of siblings who donate HSCs to these patients. Data regarding the donation-related experiences of older donors is lacking. The Related Donor Safety Study (RDSafe) aimed to examine/compare health-related quality of life (HRQoL) of older versus younger HSC donors. 60 peripheral blood stem cell (PBSC) donors ages 18–60 and 104 PBSC donors age >60 completed validated questionnaires at pre-donation, 4 weeks and 1 year post-donation. Prior to donation, older donors had poorer general physical health (t=−3.27; p=.001) but better mental health (t=2.11; p<.05). There were no age differences in multiple other donation-related factors. At 4 weeks post-donation, there were no group differences in general physical/mental health, but older donors were less likely to report donation-related pain (t=−2.26; p<.05) and concerns (t=−3.38; p=.001). At both 4 weeks and 1 year post-donation, there were no significant differences in the percentage of each age group feeling physically back to normal or in the number of days it took donors to feel completely well. There was no evidence that increasing age within the older donor group was associated with poorer donation-related HRQoL. Taken together, these data support the current practice of HSC donation by sibling donors above age 60, providing no evidence of worsening HRQoL up to one year after donation in individuals up to age 76.

show abstract

Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee

Cited by 44 publications

References 49 publications

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

Granulocyte‐colony stimulating factor administration among hemoglobin S trait donors: A single center experience from the Eastern Mediterranean region

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study

Contact Info

Product

Resources

About